CompletedNot Applicable

Intra-arterial Prostaglandin Therapy in Non-occlusive Mesenteric Ischemia

Germany42 participantsStarted 2018-10-01

Plain-language summary

Minimal invasive intra-arterial prostaglandin therapy is currently being offered as an established and safe treatment approach for Non-occlusive mesenteric ischemia (NOMI). So far, there are no data that prospective evaluate clinical response parameters of this method and corresponding criteria for response. The investigators are therefore planning a prospective observational study on NOMI patients with the aim to collect 1. routine clinical data, 2. data from advanced angigraphic imaging and 3. data from blood biomarkers of intestinal ischemia before/at implementation of intra-arterial vasodilatory therapy. From these three data packages, the investigators hope to subsequentially derive criteria to better predict response to therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- persistent shock: Norepinephrine dose \> 0.2ug/kg/min over \> 48hrs and * intestinal failure: paralytic ileus \> 24hrs despite neostigmine therapy or * new onset progressive organ failure (2 out of six criteria): Norepinephrine dose increase, rise in serum lactate, decrease in Horowitz index, new renal replacement therapy, rise in bilirubin, rise in INR, or all of the following: rise in ALT, AST, CK and LDH Exclusion Criteria: * patients \< 18 years old * pregnancy

What they're measuring

Improvement of ischemia

Timeframe: 24 hours following intervention

Trial details

NCT IDNCT04235634

SponsorHannover Medical School

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-12-31

View on ClinicalTrials.gov More Non-Occlusive Mesenteric Ischaemia (NOMI) trials